SCHEMBL3353020

SCHEMBL3353020

OCC1(O)CCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1366344 0.97 ESR2 (0.33)
SCHEMBL24791394 0.90 SLC6A2 (0.38)
Hydrochloric Acid SCHEMBL1880406 0.88 SLC6A2 (0.39)
SCHEMBL16553599 0.83
SCHEMBL12285716 0.83
Trifluoroacetic Acid SCHEMBL2079996 0.81 HRH4 (0.33)
SCHEMBL2695845 0.78 DRD2 (0.30)
SCHEMBL128734 0.77
SCHEMBL14128934 0.77 ESR2 (0.41)
Hydrochloric Acid SCHEMBL18150816 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109631-A1 SYNTHETIC DELIVERY SYSTEMS AND CONJUGATES THEREOF MICRO CRISPR PVT. LTD. (IN) 2025-05-30 WO claimed
CN-114746411-B Substituted tricyclic compounds 印度鲁宾有限公司 2024-06-25 CN claimed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 EP claimed
CN-114746411-A Substituted tricyclic compounds 印度鲁宾有限公司 2022-07-12 CN claimed
CN-122070287-A IRAK 4-targeted degradation agent compound and application thereof 江苏先声药业有限公司 2026-05-19 CN disclosed
EP-4722209-A1 PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Shenogen Pharma Group (CN) 2026-04-08 EP disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 US disclosed
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 US disclosed
US-12421211-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 US disclosed
WO-2025109631-A1 SYNTHETIC DELIVERY SYSTEMS AND CONJUGATES THEREOF MICRO CRISPR PVT. LTD. (IN) 2025-05-30 WO disclosed
WO-2025087291-A1 IRAK4 TARGETED DEGRADATION AGENT COMPOUND, AND USE THEREOF 江苏先声药业有限公司 2025-05-01 WO disclosed
US-6528534-B2 Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes MILLENNIUM PHARMACEUTICALS, INC. 2003-03-04 US disclosed
US-20020013325-A1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation FISHER MATTHEW J (US) 2002-01-31 US disclosed
US-6291469-B1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation ELI LILLY AND COMPANY 2001-09-18 US disclosed
CN-1275124-A Phthalazine derivatives and remedies for erectile dysfunction EISAI CO LTD (JP) 2000-11-29 CN disclosed
EP-0854869-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1998-07-29 EP disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 US disclosed
WO-1997011940-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1997-04-03 WO disclosed
US-3998827-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1976-12-21 US disclosed